{"id":7148,"date":"2025-04-28T11:06:41","date_gmt":"2025-04-28T09:06:41","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=7148"},"modified":"2025-04-28T21:16:21","modified_gmt":"2025-04-28T19:16:21","slug":"first-line-tislelizumab-plus-chemotherapy-for-esophageal-squamous-cell-carcinoma-with-programmed-death-ligand-1-expression-%e2%89%a5-1-a-retrospective-analysis-of-rationale-306","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/first-line-tislelizumab-plus-chemotherapy-for-esophageal-squamous-cell-carcinoma-with-programmed-death-ligand-1-expression-%e2%89%a5-1-a-retrospective-analysis-of-rationale-306\/","title":{"rendered":"First-line tislelizumab plus chemotherapy for esophageal squamous cell carcinoma with programmed death-ligand 1 expression \u2265 1%: a retrospective analysis of RATIONALE-306"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-7148","publication","type-publication","status-publish","hentry","disease_state-esophageal-squamous-cell-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/7148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7148"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}